The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Signaling pathways perturbing muscle mass.
Abstract
Purpose of review To discuss the mechanisms of muscle loss during cachexia. Recent findings Cachexia can be defined as a wasting of lean body mass that cannot be reversed nutrionally, indicating a dysregulation in the pathways maintaining body composition. In skeletal muscle, during cachexia, there is an upregulation of protein degradation. A search for transcriptional markers of muscle atrophy led to the discovery of the E3 ubiquitin ligases MuRF1 and MAFbx (also called Atrogin-1). These genes are upregulated in multiple models of atrophy and cachexia. They target particular protein substrates for degradation via the ubiquitin/proteasome pathway. The insulin-like growth factor-1 can block the transcriptional upregulation of MuRF1 and MAFbx via the phosphatidylinositol-3 kinase/Akt/Foxo pathway. MuRF1's substrates include several components of the sarcomeric thick filament, including myosin heavy chain. Thus, by blocking MuRF1, insulin-like growth factor-1 prevents the breakdown of the thick filament, particularly myosin heavy chain, which is asymmetrically lost in settings of cortisol-linked skeletal muscle atrophy. Insulin-like growth factor-1/phosphatidylinositol-3 kinase/Akt signaling also dominantly inhibits the effects of myostatin, which is a member of the transforming growth factor-[beta] family of proteins. Deletion or inhibition of myostatin causes a significant increase in skeletal muscle size. Recently, myostatin has been shown to act both by inhibiting gene activ…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These two systems are controlled by a transcriptional program that upregulates several crucial and rate-limiting enzymes (Glass, 2010; Jagoe and Goldberg, 2001).”
From Proteasome dysfunction induces muscle growth defects and protein aggregation (2014) · cites this paper as Glass, 2010
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Identification of ubiquitin ligases required for skeletal muscle atrophy.
Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K.-M., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., et al. (2001) · Science · doi:10.1126/science.1065874 · Cited by 3,521
Self-citationSandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2004) · Cell · doi:10.1016/s0092-8674(04)00400-3 · Cited by 3,012
Bodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J. C., Glass, D. J., et al. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1014 · Cited by 2,752
Self-citationDouble muscling in cattle due to mutations in the myostatin gene
McPherron, A. C., & Lee, S.-J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12457 · Cited by 2,039
Stitt, T. N., Drujan, D., Clarke, B. A., Panaro, F., Timofeyva, Y., Kline, W. O., Gonzalez, M., Yancopoulos, G. D., & Glass, D. J. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00211-4 · Cited by 1,964
Self-citationFoxO3 Controls Autophagy in Skeletal Muscle In Vivo
Mammucari, C., Milan, G., Romanello, V., Masiero, E., Rudolf, R., Del Piccolo, P., Burden, S. J., Di Lisi, R., Sandri, C., Zhao, J., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.001 · Cited by 1,953
Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy
Gomes, M. D., Lecker, S. H., Jagoe, R. T., Navon, A., & Goldberg, A. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251541198 · Cited by 1,774
Rommel, C., Bodine, S. C., Clarke, B. A., Rossman, R., Nunez, L., Stitt, T. N., Yancopoulos, G. D., & Glass, D. J. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1009 · Cited by 1,583
Self-citationA deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle
Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556
Research works printed but not linked: 1
- Stitt, 2004, Mol Cell, 14, 395, 10.1016/S1097-2765(04)00211-4 · DOI · Paper page
Cited by
Cancer cachexia: understanding the molecular basis
Argilés, J. M., Busquets, S., Stemmler, B., & López-Soriano, F. J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3829 · Cited by 1,517
Branched-chain amino acids in metabolic signalling and insulin resistance
Lynch, C. J., & Adams, S. H. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.171 · Cited by 1,461
Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways
Fearon, K. C. H., Glass, D. J., & Guttridge, D. C. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.06.011 · Cited by 1,205
“These two signaling mediators are required to upregulate the expression of the key E3 ligases (muscle RING finger-containing protein 1, MURF1, and muscle atrophy F box protein, MAFbx, otherwise known as Atrogin-1), which mediate sarcomeric breakdown and inhibition of protein synthesis (Glass, 2010).”
BackgroundSelf-citationAberrant repair and fibrosis development in skeletal muscle
Mann, C. J., Perdiguero, E., Kharraz, Y., Aguilar, S., Pessina, P., Serrano, A. L., & Muñoz-Cánoves, P. (2011) · Skeletal Muscle · doi:10.1186/2044-5040-1-21 · Cited by 853
“Deficiency of myostatin increases skeletal muscle mass, myofiber diameter and strength [93,94].”
BackgroundBonetto, A., Aydogdu, T., Jin, X., Zhang, Z., Zhan, R., Puzis, L., Koniaris, L. G., & Zimmers, T. A. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00039.2012 · Cited by 463
Muscle wasting and cachexia in heart failure: mechanisms and therapies
von Haehling, S., Ebner, N., dos Santos, M. R., Springer, J., & Anker, S. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.51 · Cited by 421
Roberts, E. W., Deonarine, A., Jones, J. O., Denton, A. E., Feig, C., Lyons, S. K., Espeli, M., Kraman, M., McKenna, B., Wells, R. J. B., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20122344 · Cited by 414
“…E3 ubiquitin ligases, muscle atrophy F-box/atrogin-1, and muscle RING finger protein/MuRF1 (Bodine et al., 2001; Gomes et al., 2001; Glass, 2010), which ubiquitinate muscle-specific proteins and promote their proteasomal degradation (Bodine et al., 2001; Gomes et al., 2001; Lee et…”
BackgroundCai, Y., Song, W., Li, J., Jing, Y., Liang, C., Zhang, L., Zhang, X., Zhang, W., Liu, B., An, Y., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2161-3 · Cited by 408
Muscle protein synthesis in response to nutrition and exercise
Atherton, P. J., & Smith, K. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2011.225003 · Cited by 401
“endocrine, auto/paracrine) sensory mechanisms (Glass, 2010; West et al. 2010).”
BackgroundBodine, S. C. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.06.011 · Cited by 389
“Both MuRF1 and MAFbx have ubiquitin ligase activity and putative substrates have been identified for each E3 ligase based on binding studies and in vitro ubiquitin ligase assays (Glass, 2010).”
BackgroundMolecular and cellular mechanisms of skeletal muscle atrophy: an update
Fanzani, A., Conraads, V. M., Penna, F., & Martinet, W. (2012) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-012-0074-6 · Cited by 370
“[27, 28, 50, 51], the PI3K/Akt pathway is central and is mainly recruited upon IGF-1/insulin stimuli to promote protein syn-”
BackgroundNF-κB–mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia
He, W. A., Berardi, E., Cardillo, V. M., Acharyya, S., Aulino, P., Thomas-Ahner, J., Wang, J., Bloomston, M., Muscarella, P., Nau, P., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68523 · Cited by 357
“In cachexia, this balance is tipped toward a catabolic state resulting from activated ubiquitin proteasome and autophagy systems that promote protein breakdown as well as from reduced Akt and mTOR activities that decrease protein synthesis (6).”
Dodson, S., Baracos, V. E., Jatoi, A., Evans, W. J., Cella, D., Dalton, J. T., & Steiner, M. S. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-061509-131248 · Cited by 319
“Significant advances have been made in elucidating the signaling pathways that control expression of these two ubiquitin ligases (28).”
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential
Han, H. Q., Zhou, X., Mitch, W. E., & Goldberg, A. L. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.019 · Cited by 314
Li, C., Yu, K., Shyh‐Chang, N., Li, G., Jiang, L., Yu, S., Xu, L., Liu, R., Guo, Z., Xie, H., et al. (2019) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12417 · Cited by 280
“pathway via the FGF-inducible 14 receptor, leading to increased expression of MuRF1 and activation of the ubiquitin-proteasome pathway.(4) In fact, the other proinflam-”
BackgroundMicrovesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7
He, W. A., Calore, F., Londhe, P., Canella, A., Guttridge, D. C., & Croce, C. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402714111 · Cited by 235
Skeletal Muscle Wasting and Renewal: A Pivotal Role of Myokine IL-6
Belizário, J. E., Fontes-Oliveira, C. C., Borges, J. P., Kashiabara, J. A., & Vannier, E. (2016) · SpringerPlus · doi:10.1186/s40064-016-2197-2 · Cited by 244
Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice
Paul, P. K., Gupta, S. K., Bhatnagar, S., Panguluri, S. K., Darnay, B. G., Choi, Y., & Kumar, A. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201006098 · Cited by 227
“Interestingly, JCB • VOLUME 191 • NUMBER 7 • 2010 1400 have been found to be highly expressed in atrophying muscles (Bodine et al., 2001; Gomes et al., 2001).”
InfluentialHyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis
Qiu, J., Tsien, C., Thapalaya, S., Narayanan, A., Weihl, C. C., Ching, J. K., Eghtesad, B., Singh, K., Fu, X., Dubyak, G., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00183.2012 · Cited by 214
“However, a reduction in skeletal muscle protein synthesis alone is not sufficient to account for continued reduction in muscle mass in cirrhosis, and an increase in proteolysis is necessary (18).”
BackgroundPrevention of liver cancer cachexia-induced cardiac wasting and heart failure
Springer, J., Tschirner, A., Haghikia, A., von Haehling, S., Lal, H., Grzesiak, A., Kaschina, E., Palus, S., Pötsch, M., von Websky, K., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht302 · Cited by 210
Wada, S., Kato, Y., Okutsu, M., Miyaki, S., Suzuki, K., Yan, Z., Schiaffino, S., Asahara, H., Ushida, T., & Akimoto, T. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.271270 · Cited by 203
Cellular and Molecular Mechanisms Regulating Fibrosis in Skeletal Muscle Repair and Disease
Serrano, A. L., Mann, C. J., Vidal, B., Ardite, E., Perdiguero, E., & Muñoz-Cánoves, P. (2011) · Current Topics in Developmental Biology · doi:10.1016/b978-0-12-385940-2.00007-3 · Cited by 200
“It is specifically expressed in the skeletal muscle lineage and is a major negative regulator of muscle growth such that myostatin deficiency increases skeletal muscle mass, myofiber diameter, and strength (Glass, 2010; Kollias and McDermott, 2008).”
BackgroundJohns, N., Stephens, N. A., & Fearon, K. C. H. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.032 · Cited by 183
Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle
Wang, G., Biswas, A. K., Ma, W., Kandpal, M., Coker, C., Grandgenett, P. M., Hollingsworth, M. A., Jain, R., Tanji, K., Lόpez-Pintado, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0054-2 · Cited by 188
“Myofibrillar proteins comprise over 70% of muscle proteins, and their reduced synthesis or loss negatively affects fiber size and function 6,40 .”
Carson, J. A., & Manolagas, S. C. (2015) · Bone · doi:10.1016/j.bone.2015.04.015 · Cited by 168
“Muscle growth or atrophy closely correlates with a positive and negative balance between protein accretion and degradation, respectively [77, 78].”
BackgroundMuscle–bone interactions: basic and clinical aspects
Cianferotti, L., & Brandi, M. L. (2014) · Endocrine · doi:10.1007/s12020-013-0026-8 · Cited by 167
“protein degradation and induce myoblast apoptosis, thus producing muscle wasting [35].”
BackgroundAntioxidant and Adaptative Response Mediated by Nrf2 during Physical Exercise
Vargas-Mendoza, N., Morales-González, Á., Madrigal-Santillán, E. O., Madrigal-Bujaidar, E., Álvarez-González, I., García-Melo, L. F., Anguiano-Robledo, L., Fregoso-Aguilar, T., & Morales-Gonzalez, J. A. (2019) · Antioxidants · doi:10.3390/antiox8060196 · Cited by 162
“Myostatin negatively controls muscular growth [106]; therefore, the repression of the myostatin signaling pathway inhibits the transcription of genes implicated in protein synthesis, stimulating muscular anabolism by means of the regulation of the Akt/mTOR pathway [90,107,108].”
BackgroundEffect of Prehabilitation on the Outcome of Anterior Cruciate Ligament Reconstruction
Shaarani, S. R., O’Hare, C., Quinn, A., Moyna, N. M., Moran, R., & O’Byrne, J. (2013) · The American Journal of Sports Medicine · doi:10.1177/0363546513493594 · Cited by 172
“In addition, a study has shown that MHC isoforms did not differ after 6 weeks of bed rest, concluding that muscle unloading in humans does not always induce important changes in fiber type or MHC composition in vivo.(22) It is argued that skeletal muscle adaptations would not depend on a single ‘‘master switch’’ but r…”
BackgroundIncreased Proteolysis, Myosin Depletion, and Atrophic AKT-FOXO Signaling in Human Diaphragm Disuse
Levine, S., Biswas, C., Dierov, J. K., Barsotti, R., Shrager, J. B., Nguyen, T., Sonnad, S. S., Kucharchzuk, J. C., Kaiser, L. R., Singhal, S. K., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200910-1487oc · Cited by 166
“, noncanonical) nuclear factor–kB (29, 32, 33); P-38 mitogenactivated protein kinase (34, 35); myostatin (28, 35), other members of the transforming growth factor–b family (28, 36, 37).”
BackgroundThe central role of hypothalamic inflammation in the acute illness response and cachexia
Burfeind, K. G., Michaelis, K. A., & Marks, D. L. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.10.038 · Cited by 156
Rolland, Y., van Kan, G. A., Guyonnet, S., & Vellas, B. J. (2010) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e328340c2c2 · Cited by 185
The SCF-Fbxo40 Complex Induces IRS1 Ubiquitination in Skeletal Muscle, Limiting IGF1 Signaling
Shi, J., Luo, L., Eash, J. K., Ibebunjo, C., & Glass, D. J. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.09.011 · Cited by 165
“treatment, polyubiquitinated IRS1 increased upon IGF1 treatment (Figure 1C, left panel), while total ubiquitinated proteins actually decreased slightly (Figure 1C, right panels), as might be expected given IGF1’s antiatrophy effects (Glass, 2010).”
BackgroundSelf-citationSkeletal Muscle Dysfunction in Idiopathic Pulmonary Arterial Hypertension
Batt, J. A. E., Ahmed, S. S., Correa, J., Bain, A. D., & Granton, J. T. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0506oc · Cited by 154
“Skeletal muscle atrophy contributes to muscle weakness and represents an imbalance between synthesis and degradation of myofiber structural and contractile proteins, with proteolysis overwhelming the muscle’s synthetic capacity (18, 19).”
BackgroundSarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass
Sakuma, K., & Yamaguchi, A. (2012) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1007/s13539-011-0052-4 · Cited by 137
“3-kinase (PI3K) which is involved in the Akt-mTOR (mammalian target of rapamycin) signaling pathway leading to protein anabolism [63, 64].”
BackgroundMechanisms of muscle growth and atrophy in mammals and Drosophila
Piccirillo, R., Demontis, F., Perrimon, N., & Goldberg, A. L. (2013) · Developmental Dynamics · doi:10.1002/dvdy.24036 · Cited by 161
Pericytes: multitasking cells in the regeneration of injured, diseased, and aged skeletal muscle
Birbrair, A., Zhang, T., Wang, Z., Messi, M. L., Mintz, A., & Delbono, O. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00245 · Cited by 152
“Ander Izeta, Instituto Investigación Sanitaria Biodonostia, Spain”
Backgroundden Kamp, C. M. O., LANGEN, R. C. J., Snepvangers, F. J. M., de Theije, C. C., Schellekens, J. M., Laugs, F., Dingemans, A. C., & Schols, A. M. W. J. (2013) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.058388 · Cited by 140
Guerci, A., Lahoute, C., Hébrard, S., Collard, L., Graindorge, D., Favier, M., Cagnard, N., Batonnet‐Pichon, S., Précigout, G., García, L., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.12.001 · Cited by 152
“Anabolic hormones, such as insulin-like growth factor 1 (IGF1), induce myofiber hypertrophy by activating the Akt1 pathway and the translational machinery through mTOR, S6K1, and 4E-BP1 (Glass, 2010).”
BackgroundSebastiano, K. M. D., Yang, L., Zbuk, K. M., Wong, R. K. W., Chow, T., Koff, D., Moran, G. R., & Mourtzakis, M. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114512001067 · Cited by 141
“Patients with the most accelerated tissue losses may exhibit increased stimulation of the catabolic pathways associated with muscle and adipose wasting, such as increased pro-inflammatory processes, and inhibition of the anabolic pathways((25,26)).”
BackgroundRecent advances in the biology and therapy of muscle wasting
Glass, D. J., & Roubenoff, R. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05809.x · Cited by 146
“(1) shrinking: weight loss, unintentional, of 10 pounds or 5% of body weight in prior year; (2) weakness: grip strength in the lowest 20% at baseline, adjusted for gender and body mass index; (3) poor endurance and energy: as indicated by self-report of exhaustion; (4) slowness: the slowest 20% of the population was d…”
MethodSelf-citationRole of Pro-inflammatory Cytokines in Regulation of Skeletal Muscle Metabolism: A Systematic Review
Sharma, B., & Dabur, R. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867326666181129095309 · Cited by 142
Myostatin: more than just a regulator of muscle mass
Argilés, J. M., Orpí, M., Busquets, S., & López-Soriano, F. J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.02.001 · Cited by 125
Siddiqui, J. A., Pothuraju, R., Jain, M., Batra, S. K., & Nasser, M. W. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188359 · Cited by 134
Satellite cell senescence underlies myopathy in a mouse model of limb-girdle muscular dystrophy 2H
Kudryashova, E., Kramerova, I., & Spencer, M. J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59581 · Cited by 119
“The PI3K/ AKT signaling pathway is a key regulator of skeletal muscle growth (33, 34).”
Mammalian Target of Rapamycin (mTOR) Signaling Network in Skeletal Myogenesis
Ge, Y., & Chen, J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.406942 · Cited by 123
NF-κB Signaling in Skeletal Muscle Health and Disease
Peterson, J. M., Bakkar, N., & Guttridge, D. C. (2011) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/b978-0-12-385940-2.00004-8 · Cited by 156
Andrés‐Mateos, E., Brinkmeier, H., Burks, T. N., Mejías, R., Files, D. C., Steinberger, M., Soleimani, A. A., Marx, R., Simmers, J. L., Lin, B., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201443 · Cited by 117
Murphy, K. T., Chee, A., Trieu, J., Naim, T., & Lynch, G. S. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.008839 · Cited by 120
“Most of these alterations were significantly correlated with atrogin-1 and MuRF-1 mRNA expression, supporting a major role of the ubiquitin ligases in the pathogenesis of cancer cachexia (Glass, 2010).”
Molecular Mechanisms and Treatment Options for Muscle Wasting Diseases
Rüegg, M. A., & Glass, D. J. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100537 · Cited by 125
Self-citationBelghit, I., Cassy, S., Geurden, I., Dias, K., Surget, A., Kaushik, S., Panserat, S., & Seiliez, I. (2014) · British Journal Of Nutrition · doi:10.1017/s0007114514001226 · Cited by 130
Skeletal muscle dysfunction in critical care: Wasting, weakness, and rehabilitation strategies
Puthucheary, Z., Harridge, S. D. R., & Hart, N. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181f2458d · Cited by 117
“Myostatin knockout animal models exhibit a markedly hypertrophied phenotype; natural inhibitors of myostatin may have therapeutic value (85).”
BackgroundThe PKB/FOXO switch in aging and cancer
Kloet, D. E. A., & Burgering, B. M. T. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.04.003 · Cited by 111
TAK-1/p38/nNFκB signaling inhibits myoblast differentiation by increasing levels of Activin A
Trendelenburg, A. U., Meyer, A. S., Jacobi, C., Feige, J. N., & Glass, D. J. (2012) · Skeletal Muscle · doi:10.1186/2044-5040-2-3 · Cited by 117
“The phosphoinositide 3-kinase (PI3K)/AKT pathway is also activated during myogenesis, and insulin-like growth factor (IGF)-1, which initiates PI3K/AKT signaling, is able to induce both differentiation of myoblasts [5,6], and hypertrophy of post-differentiated myotubes [25-29].”
BackgroundSelf-citationCarson, J. A., Hardee, J. P., & VanderVeen, B. N. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.11.005 · Cited by 120
Mediators and Patterns of Muscle Loss in Chronic Systemic Inflammation
Pérez-Baos, S., Prieto‐Potín, I., Roman‐Blas, J. A., Sánchez‐Pernaute, O., Largo, R., & Herrero‐Beaumont, G. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00409 · Cited by 114
“The UPS accounts for the principal mechanism of protein degradation in muscle cells (Glass, 2010; Milan et al., 2015).”
BackgroundMethodCachexia and pancreatic cancer: are there treatment options?
Mueller, T., Burmeister, M.-A., Bachmann, J., & Martignoni, M. E. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i28.9361 · Cited by 124
TWEAK and TRAF6 regulate skeletal muscle atrophy
Kumar, A., Bhatnagar, S., & Paul, P. K. (2012) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e328351c3fc · Cited by 95
“Further, the ubiquitin–proteasome system (UPS) has now emerged as a major proteolytic system involved in myofibril proteolysis in a variety of catabolic conditions [2,3].”
BackgroundInfluentialMueller, T. C., Bachmann, J., Prokopchuk, O., Friess, H., & Martignoni, M. E. (2016) · BMC Cancer · doi:10.1186/s12885-016-2121-8 · Cited by 95
“Furthermore, the activation of the transcription factors Smad2/3 (myostatin pathway) also increases the expression of MuRF-1 and MAfxb via FoxO [4, 58, 59, 61, 62, 104, 113, 121].”
BackgroundInfluentialClinical Classification of Cancer Cachexia: Phenotypic Correlates in Human Skeletal Muscle
Johns, N., Hatakeyama, S., Stephens, N. A., Degen, M., Degen, S., Frieauff, W., Lambert, C., Ross, J. A., Roubenoff, R., Glass, D. J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083618 · Cited by 106
Self-citationDrescher, C., Konishi, M., Ebner, N., & Springer, J. (2015) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12082 · Cited by 102
“15 The involvement of the NFκB pathway was originally observed in a model of disuse atrophy41 where it binds directly to the MuRF-1.”
BackgroundInfluentialVerzola, D., Procopio, V., Sofia, A., Villaggio, B., Tarroni, A., Bonanni, A., Mannucci, I., Cian, F. D., Gianetta, E., Saffioti, S., et al. (2011) · Kidney International · doi:10.1038/ki.2010.494 · Cited by 102
“The effects of myostatin on the rodent skeletal muscle include inhibition of protein synthesis and MyoD expression with an increase in atrogin-1.(38,39) However, the interpretation of the direct and/or interactive effects of apoptosis, protein turnover, and myostatin is confounded by intricate physiological relationsh…”
BackgroundTargeting the myostatin signaling pathway to treat muscle wasting diseases
Han, H. Q., & Mitch, W. E. (2011) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e32834bddf9 · Cited by 108
The p97/VCP ATPase is critical in muscle atrophy and the accelerated degradation of muscle proteins
Piccirillo, R., & Goldberg, A. L. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.178 · Cited by 85
“Normal growth of muscle requires the IGF1/insulin-signal-ling pathway to enhance protein synthesis and reduce FoxO3-activated proteolysis (Sandri et al , 2004; Stitt et al , 2004; Glass, 2010).”
Marceca, G. P., Londhe, P., & Calore, F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00298 · Cited by 92
“Both these enzymes mediate myofibrillar protein breakdown by acting on several components of the sarcomeric thick filament, including myosin heavy chain (MHC), and are thought to interfere with processes related to protein synthesis (99).”
BackgroundRivas, D. A., Morris, E. P., Haran, P. H., Pasha, E. P., Morais, M. D. S., Dolnikowski, G. G., Phillips, E. M., & Fielding, R. A. (2012) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00412.2012 · Cited by 105
Proserpio, V., Fittipaldi, R., Ryall, J. G., Sartorelli, V., & Caretti, G. (2013) · Genes & Development · doi:10.1101/gad.217240.113 · Cited by 110
“Signaling molecules such as myostatin, catabolic steroids, and proinflammatory cytokines have been identified as factors contributing to the atrophic process in skeletal muscle (Glass 2010b).”
BackgroundInfluentialKohsaka, H., Mimori, T., Kanda, T., Shimizu, J., Sunada, Y., Fujimoto, M., Kawaguchi, Y., Jinnin, M., Muro, Y., Ishihara, S., et al. (2018) · Modern Rheumatology · doi:10.1080/14397595.2018.1521185 · Cited by 87
Bhatnagar, S., Mittal, A., Gupta, S. K., & Kumar, A. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22821 · Cited by 90
“In catabolic states where proteolysis is increased, two genes specific to muscle atrophy, MuRF1 and MAFbx, are highly upregulated (Cao et al., 2005; Glass, 2010).”
BackgroundGlycogen synthase kinase-3β is required for the induction of skeletal muscle atrophy
Verhees, K. J. P., Schols, A. M. W. J., KELDERS, M. C. J. M., den Kamp, C. M. O., van der Velden, J. L. J., & LANGEN, R. C. J. (2011) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00520.2010 · Cited by 90
Understanding the molecular basis of anorexia and tissue wasting in cancer cachexia
Yeom, E., & Yu, K. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00752-w · Cited by 95
Minetti, G., Feige, J. N., Rosenstiel, A., Bombard, F., Meier, V., Werner, A., Bassilana, F., Sailer, A. W., Kahle, P., Lambert, C., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2002038 · Cited by 90
“Skeletal muscle mass is maintained by signaling pathways that control cell proliferation, differentiation, protein synthesis, and degradation (1, 2).”
BackgroundSelf-citationOsteoporosis and sarcopenia: the connections
Tarantino, U., Baldi, J., Celi, M., Rao, C., Liuni, F. M., Iundusi, R., & Gasbarra, E. (2013) · Aging Clinical and Experimental Research · doi:10.1007/s40520-013-0097-7 · Cited by 86
“Akt, through different downstream mediators, promotes protein synthesis and retards protein degradation by regulating the expression of various atrogenes [20, 21].”
BackgroundSarcopenia, cachexia, and muscle performance in heart failure: Review update 2016
Saitoh, M., Ishida, J., Doehner, W., von Haehling, S., Anker, M. S., Coats, A. J. S., Anker, S. D., & Springer, J. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.155 · Cited by 89
Myostatin: a skeletal muscle chalone
Lee, S.-J. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012422-112116 · Cited by 84
Telemedicine: medical, legal and ethical perspectives.
Clark, P. A., Capuzzi, K. M., & Harrison, J. (2010) · PubMed · Cited by 113
Liu, Q., Zha, X., Faralli, H., Yin, H., Louis‐Jeune, C., Perdiguero, E., Pranckevičienė, E., Muñoz‐Cánoves, P., Rudnicki, M. A., Brand, M., et al. (2012) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjs045 · Cited by 102
“Among the signaling pathways that regulate myogenesis (Luo et al., 2005; Glass, 2010; Jang et al., 2012), the p38 MAPK signaling pathway is one of the most characterized (Zetser et al., 1999; Wu et al., 2000; Cabane et al., 2003; Keren et al., 2006; Perdiguero et al., 2007).”
BackgroundProteasome dysfunction induces muscle growth defects and protein aggregation
Kitajima, Y., Tashiro, Y., Suzuki, N., Warita, H., Kato, M., Tateyama, M., Ando, R., Izumi, R., Yamazaki, M., Abe, M., et al. (2014) · Journal of Cell Science · doi:10.1242/jcs.150961 · Cited by 79
“, Glass, D. J. et al. (2004). IKKbeta/ NF-kappaB activation causes severe muscle wasting in mice. Cell 119, 285298. Carmignac, V., Quéré, R. and Durbeej, M. (2011). Proteasome inhibition improves the muscle of laminin a2 chain-deficient mice.”
BackgroundInfluentialToward a Definition of Sarcopenia
Cederholm, T., Bauer, J. M., Boirie, Y., Schneider, S. M., Sieber, C. C., & Rolland, Y. (2011) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2011.04.001 · Cited by 92
Glover, E. I., & Phillips, S. M. (2010) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32833f1ae5 · Cited by 86
The administration of Fructus Schisandrae attenuates dexamethasone-induced muscle atrophy in mice
Kim, J. W., Ku, S., Han, M. H., Kim, K. Y., Kim, S. G., Kim, G., Hwang, H. J., Kim, B. W., Kim, C. M., & Choi, Y. H. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2200 · Cited by 79
“The resulting decrease in physical activity induces further skeletal muscle atrophy, leading to a vicious cycle of atrophic processes (1,2).”
InfluentialDahiya, S., Bhatnagar, S., Hindi, S. M., Jiang, C., Paul, P. K., Kuang, S., & Kumar, A. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr362 · Cited by 83
“In addition to Akt kinase, several other signaling proteins, especially mitogen-activated protein kinases (MAPKs), have been implicated in skeletal muscle remodeling in the conditions of hypertrophy and/or atrophy (39).”
BackgroundDkk3 dependent transcriptional regulation controls age related skeletal muscle atrophy
Yin, J., Yang, L., Xie, Y., Liu, Y., Li, S., Yang, W., Xu, B., Ji, H., Ding, L., Wang, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04038-6 · Cited by 72
Al‐Qusairi, L., Prokic, I., Amoasii, L., Kretz, C., Messaddeq, N., Mandel, J., & Laporte, J. (2013) · The FASEB Journal · doi:10.1096/fj.12-220947 · Cited by 86
“Moreover, the up-regulation of at least Atrogin1 and Murf1 is substantially decreased upon ectopic expression of Mtm1 during 2 wk following AAV transduction.”
BackgroundInfluentialDifferential features of muscle fiber atrophy in osteoporosis and osteoarthritis
Terracciano, C., Celi, M., Lecce, D., Baldi, J., Rastelli, E., Lena, E., Massa, R., & Tarantino, U. (2013) · Osteoporosis International · doi:10.1007/s00198-012-1990-1 · Cited by 75
Dasarathy, J., Alkhouri, N., & Dasarathy, S. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02498.x · Cited by 74
“Reduction in circulating leptin would improve appetite, decrease skeletal muscle AMPK phosphorylation with subsequent improvement in muscle protein synthesis (67).”
BackgroundTWEAK/Fn14 Signaling Axis Mediates Skeletal Muscle Atrophy and Metabolic Dysfunction
Sato, S., Ogura, Y., & Kumar, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00018 · Cited by 76
“Curr Opin Clin Nutr Metab Care (2004) 7(3):265–9.”
BackgroundInfluentialSarcopenia and chemotherapy-mediated toxicity
Vega, M. C. M. D., Centro Brasileiro de Radioterapia, O. E. M., Laviano, A., & Pimentel, G. D. (2016) · Einstein (São Paulo) · doi:10.1590/s1679-45082016md3740 · Cited by 94
“activin A acts on its receptor, activating the SMADs 2/3, inhibiting the AKT/mTOR signaling, and leading to muscle atrophy; at the same time, the activation of the muscle RING finger-containing protein 1 (MURF-1) and the muscle atrophy F box protein (MAFbx/atrogin) occurs, potentiating skeletal muscle and strength and…”
BackgroundMG132-mediated inhibition of the ubiquitin–proteasome pathway ameliorates cancer cachexia
Zhang, L., Tang, H., Kou, Y., Li, R., Zheng, Y., Wang, Q., Zhou, X., & Jin, L. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1412-6 · Cited by 78
“In agreement with a previous study which showed that inhibiting the expression of MuRF1 and MAFbx could reverse skeletal muscle atrophy and muscle protein degradation (Glass 2010), we showed that MG132 significantly”
ResultRudolf, R., Bogomolovas, J., Strack, S., Choi, K. R., Khan, M. M., Wagner, A., Brohm, K., Hanashima, A., Gasch, A., Labeit, D., et al. (2012) · AGE · doi:10.1007/s11357-012-9468-9 · Cited by 71
“Thereby, induction of atrophy-associated E3 ligases is thought to induce muscle atrophy by the degradation of sarcomeric muscle proteins, including in particular myosin, actin, and troponin I (Bodine et al. 2001; Glass 2005, 2010; Adams et al. 2008).”
Regulatory circuitry of TWEAK‐Fn14 system and PGC‐1α in skeletal muscle atrophy program
Hindi, S. M., Mishra, V. K., Bhatnagar, S., Tajrishi, M. M., Ogura, Y., Yan, Z., Burkly, L. C., Zheng, T. S., & Kumar, A. (2013) · The FASEB Journal · doi:10.1096/fj.13-242123 · Cited by 72
“The UPS is one of the major pathways that cause degradation of bulk of muscle proteins in various atrophying conditions (44).”
BackgroundIron Metabolism of the Skeletal Muscle and Neurodegeneration
Hałoń, M., Borkowska, A., Herman-Antosiewicz, A., & Antosiewicz, J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00165 · Cited by 82
“…muscle by inhibiting Akt Frontiers in Neuroscience | www.frontiersin.org 2 March 2019 | Volume 13 | Article 165 kinase, which regulates the muscle mass by inhibiting protein degradation and promoting protein synthesis (Morissette et al., 2009; Trendelenburg et al., 2009; Glass, 2010; Figure 1).”
BackgroundThe TWEAK-Fn14 pathway: A potent regulator of skeletal muscle biology in health and disease
Tajrishi, M. M., Zheng, T. S., Burkly, L. C., & Kumar, A. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.12.004 · Cited by 71
“Muscle wasting is considerably inhibited in mice null for MuRF1 or MAFBx compared to wild-type mice in response to a wide variety of stimuli, suggesting that these ubiquitin ligases are the master drivers of muscle proteolysis [29].”
Lambertucci, A. C., Lambertucci, R. H., Hirabara, S. M., Curi, R., Moriscot, A. S., Alba-Loureiro, T. C., Guimarães-Ferreira, L., Levada-Pires, A. C., Vasconcelos, D. A. A., Sellitti, D. F., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050390 · Cited by 67
Increased Adenine Nucleotide Degradation in Skeletal Muscle Atrophy
Miller, S. G., Hafen, P. S., & Brault, J. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010088 · Cited by 71
“Skeletal muscle disuse is a broadly used term that encompasses reductions in mechanical loading and muscle activity such as spaceflight, bed rest, limb immobilization, and limb suspension [113].”
BackgroundJiang, Q., Yan, M., Zhao, Y., Zhou, X., Yin, L. W., Feng, L., Liu, Y., Jiang, W., Wu, P., Wang, Y., et al. (2021) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/s40104-021-00572-4 · Cited by 67
Impaired regeneration: A role for the muscle microenvironment in cancer cachexia
Talbert, E. E., & Guttridge, D. C. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.009 · Cited by 73
MacDonald, E. M., Andrés‐Mateos, E., Mejías, R., Simmers, J. L., Mi, R., Park, J.-S., Ying, S., Höke, A., Lee, S., & Cohn, R. D. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.014126 · Cited by 70
“INTRODUCTION Healthy skeletal muscle maintains a balance between protein synthesis and protein degradation (Glass, 2010; McKinnell and Rudnicki, 2004).”
BackgroundInfluentialLooijaard, S. M. L. M., Hekkert, M. L. T. L., Wüst, R. C. I., Otten, R. H. J., Meskers, C. G. M., & Maier, A. B. (2020) · Acta Physiologica · doi:10.1111/apha.13516 · Cited by 73
Hansen, D., MEEUSEN, R. R., Mullens, A., & Dendale, P. (2012) · Sports Medicine · doi:10.2165/11599590-000000000-00000 · Cited by 73
Sheriff, S., Kadeer, N., Joshi, R., Friend, L. A., James, J. H., & Balasubramaniam, A. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.12.021 · Cited by 65
“It should be noted that IGF-I treatment has been shown to exhibit both anabolic and anti-catabolic effects in burn injury (DebRoy et al., 1999; Fang et al., 1998, 2005).”
Influential
Metadata
- Authors
- Glass, D. J.
- Corresponding author
- Glass, David J
- ORCID
- Glass, David J
- Venue
- Current Opinion in Clinical Nutrition and Metabolic Care
- Published
- 2010-05
- Volume
- 13
- Issue
- 3
- Pages
- 225-229
- ISSN
- 1363-1950 (ISSN-L)
- OpenAlex
- W2078192607
- Cited by
- 359
- References
- 56
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 17 · 2023: 9 · 2022: 17 · 2021: 13 · 2020: 15 · 2019: 14 · 2018: 25 · 2017: 20 · 2016: 13 · 2015: 30 · 2014: 28 · 2013: 45 · 2012: 55
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Clinical Nutrition & Metabolic Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Nursing › Nutrition and Dietetics › Muscle metabolism and nutrition
- Keywords
- cachexia, skeletal muscle atrophy, muscle mass loss, MuRF1, atrogin-1, ubiquitin-proteasome system, protein degradation, insulin-like growth factor I, phosphatidylinositol 3-kinase/Akt signaling, FOXO, myostatin, TGF-beta, myosin heavy chain, cortisol, lean body mass
- MeSH terms
- Forkhead Box Protein O1, Cachexia, Gene Expression Regulation, Hydrocortisone, Muscle Proteins, Muscular Atrophy, Organ Size, Signal Transduction, Transforming Growth Factor beta, Muscle, Skeletal, Myosin Heavy Chains, Phosphatidylinositol 3-Kinases, Ubiquitin-Protein Ligases, Proto-Oncogene Proteins c-akt, Forkhead Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.